Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 14/12/2019
SIETES contiene 92854 citas

 
 
 1 a 20 de 1688 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Anónimo. Outbreak of lung injury associated with e-cigarette use, or vaping. CDC 2019:3 de octubre. [Ref.ID 103188]
2.Enlace a cita original Cita con resumen
Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]
3.Enlace a cita original Cita con resumen
Hajek P, Phillips-Waller A, Przulj D, Pesola F, Smith KM, Bisal N, Li J, Parrott S, Sasieni P, Dawkins L, Ross L, Goniewicz M, Wu Q, McRobbie HJ. A randomized trial of e-cigarettes versus nicotine-replacement therapy. N Engl J Med 2019;380:14 de febrero. [Ref.ID 103022]
4.Enlace a cita original Cita con resumen
Gershon AS, Campitelli MA, Hawken S, Victor C, Sproule BA, Kurdyak P, Selby P. Cardiovascular and neuropsychiatric events after varenicline use for smoking cessation. Am J Respir Crit Care Med 2018;197:913-22. [Ref.ID 102579]
5. Cita con resumen
Benefits NL, Pipe A, West R, Hays JT, Tonstad S, McRae T, Lawrence D, St Aubin L, Anthenelli RM. Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers. A randomized clinical trial. JAMA Intern Med 2018;178:622-31. [Ref.ID 102506]
6. Cita con resumen
Anónimo. FDA drops boxed warning on smoking cessation drug. DIA Daily 2016:1. [Ref.ID 101000]
8. Cita con resumen
9.Tiene citas relacionadas Cita con resumen
O'Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet 2016;388:761-75. [Ref.ID 100609]
10. Cita con resumen
Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, Ascher J, Russ C, Krishen A, Evins AE. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 2016;387:2507-20. [Ref.ID 100460]
11. Cita con resumen
Lindson-Hawley N, Banting M, West R, Michie S, Shinkins B. Gradual versus abrupt smoking cessation: a randomized, controlled noninferiority trial. Ann Intern Med 2016;164:585-92. [Ref.ID 100260]
12. Cita con resumen
Anónimo. Drugs for tobacco dependence. The Medical Letter on Drug and Therapeutics Bulletin 2016;58:27-31. [Ref.ID 100127]
13. Cita con resumen
Baker TB, Piper ME, Stein JH, Smith SS, Bolt DM, Fraser DL, Fiore MC. Effects of nicotine patch vs varenicline vs combination nicotine replacement therapy on smoking cessation at 26 weeks: a randomized clinical trial. JAMA 2016;315:371-9. [Ref.ID 100093]
14. Cita con resumen
Anónimo. Effets indésirables cardiaques des substituts nicotiniques. Prescrire 2015;35:513-4. [Ref.ID 99441]
15. Cita con resumen
Anónimo. Consolidations de fracture retardées par des médicaments. Prescrire 2015;35:507-12. [Ref.ID 99440]
16. Cita con resumen
Schnoll RA, Goelz PM, Veluz-Wilkins A, Blazekovic S, Powers L, Leone FT, Gariti P, Willeyto EP, Hitsman B. Long-term nicotine replacement therapy: a randomized clinical trial. JAMA Intern Med 2015;175:504-11. [Ref.ID 99010]
17. Cita con resumen
Anónimo. Chantix (varenicline): Drug Safety Communication - FDA updates label to include potential alcohol interaction. U.S. Food and Drug Administration 2015:9 de marzo. [Ref.ID 98840]
18. Cita con resumen
Ebbert JO, Hughes JR, West RJ, Rennard SI, Russ C, McRae TD, Treadow J, Yu C-R, Dutro MP. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA 2015;313:687-94. [Ref.ID 98814]
19. Cita con resumen
Herman O. FDA advisers vote to keep black-box warning on Chantix. Journal Watch 2014:20 de octubre. [Ref.ID 98122]
20. Cita con resumen
Young K. FDA staff: Chantix should keep neuropsychiatric warning on label . Journal Watch 2014:15 de octubre. [Ref.ID 98096]
Seleccionar todas
 
 1 a 20 de 1688 siguiente >>